- $607.27m
- $370.18m
- $139.93m
- 74
- 30
- 11
- 32
Annual income statement for RxSight, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 14.7 | 22.6 | 49 | 89.1 | 140 |
| Cost of Revenue | |||||
| Gross Profit | 1.71 | 4.52 | 21.3 | 53.8 | 98.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 50.1 | 75.4 | 112 | 141 | 177 |
| Operating Profit | -35.4 | -52.8 | -63.3 | -51.9 | -36.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 27.6 | -48.7 | -66.7 | -48.6 | -27.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 27.6 | -48.7 | -66.8 | -48.6 | -27.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 27.6 | -48.7 | -66.8 | -48.6 | -27.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3.37 | -48.7 | -66.8 | -48.6 | -27.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.128 | -1.78 | -2.36 | -1.38 | -0.706 |